The centerpiece of the acquisition is petosemtamab, Merus’ bispecific antibody targeting EGFR and LGR5, which in May ...
After Emma Walmsley steps down as GSK CEO in January, Vertex Pharma’s Reshma Kewalramani will be the sole female CEO at a top ...
Applied Therapeutics has yet to confirm whether the study, posted on Clinicaltrials.gov on Friday, means it has indeed ...
By publishing complete response letters as soon as they are issued to drug sponsors, the FDA is expanding transparency in a ...
The AAV pullback comes amid Biogen’s aggressive cost-cutting campaign, which put some 1,000 jobs on the chopping block with ...
From more than 30 target action dates in the last three months of the year, BioSpace has narrowed the list to six regulatory ...
The FDA in September issued two rejections for spinal muscular atrophy therapies—both linked to manufacturing problems—and ...
In one of the first demonstrations of the impact of last year’s Loper Supreme Court decision on challenges to agency ...
Emma Walmsley, who in 2017 became the first woman to lead a major pharmaceutical company, will step down from her post as CEO of GSK. She is to be succeeded by Luke Miels, who currently serves as ...
Arguably the most well-known SERD is AstraZeneca’s Faslodex, which was approved in 2002 for breast cancer and is administered ...
Three draft recommendation documents published on Wednesday are intended to guide drug sponsors and accelerate the ...
Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback